Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease

Marco Savarese, Annalaura Torella, Olimpia Musumeci, Corrado Angelini, Guja Astrea, Luca Bello, Claudio Bruno, Giacomo Pietro Comi, Giuseppina Di Fruscio, Giulio Piluso, Giuseppe Di Iorio, Manuela Ergoli, Gaia Esposito, Marina Fanin, Olimpia Farina, Chiara Fiorillo, Arcomaria Garofalo, Teresa Giugliano, Francesca Magri, Carlo MinettiMaurizio Moggio, Luigia Passamano, Elena Pegoraro, Ester Picillo, Simone Sampaolo, Filippo Maria Santorelli, Claudio Semplicini, Bjarne Udd, Antonio Toscano, Luisa Politano, Vincenzo Nigro

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Mutations in the GAA gene may cause a late onset Pompe disease presenting with proximal weakness without the characteristic muscle pathology, and therefore a test for GAA activity is the first tier analysis in all undiagnosed patients with hyperCKemia and/or limb-girdle muscular weakness. By using MotorPlex, a targeted gene panel for next generation sequencing, we analyzed GAA and other muscle disease-genes in a large cohort of undiagnosed patients with suspected inherited skeletal muscle disorders (n = 504). In this cohort, 275 patients presented with limb-girdle phenotype and/or an isolated hyperCKemia. Mutational analysis identified GAA mutations in ten patients. Further seven affected relatives were identified by segregation studies. All the patients carried the common GAA mutation c.-32-13T >G and a second, previously reported mutation. In the subcohort of 275 patients with proximal muscle weakness and/or hyperCKemia, we identified late-onset Pompe disease in 10 patients. The clinical overlap between Pompe disease and LGMDs or other skeletal muscle disorders suggests that GAA and the genes causing a metabolic myopathy should be analyzed in all the gene panels used for testing neuromuscular patients. However, enzymatic tests are essential for the interpretation and validation of genetic results.

Original languageEnglish
Pages (from-to)586-591
JournalNeuromuscular Disorders
Volume28
Issue number7
DOIs
Publication statusPublished - 2018

Fingerprint

Glycogen Storage Disease Type II
Genes
Muscular Diseases
Mutation
Muscle Weakness
Skeletal Muscle
Extremities
Muscles
Late Onset Disorders
Pathology
Phenotype

Keywords

  • GAA
  • Gene panels
  • HyperCKemia
  • Late onset Pompe disease (LOPD)
  • LGMD
  • Metabolic myopathies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Clinical Neurology
  • Genetics(clinical)

Cite this

Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease. / Savarese, Marco; Torella, Annalaura; Musumeci, Olimpia; Angelini, Corrado; Astrea, Guja; Bello, Luca; Bruno, Claudio; Comi, Giacomo Pietro; Di Fruscio, Giuseppina; Piluso, Giulio; Di Iorio, Giuseppe; Ergoli, Manuela; Esposito, Gaia; Fanin, Marina; Farina, Olimpia; Fiorillo, Chiara; Garofalo, Arcomaria; Giugliano, Teresa; Magri, Francesca; Minetti, Carlo; Moggio, Maurizio; Passamano, Luigia; Pegoraro, Elena; Picillo, Ester; Sampaolo, Simone; Santorelli, Filippo Maria; Semplicini, Claudio; Udd, Bjarne; Toscano, Antonio; Politano, Luisa; Nigro, Vincenzo.

In: Neuromuscular Disorders, Vol. 28, No. 7, 2018, p. 586-591.

Research output: Contribution to journalArticle

Savarese, M, Torella, A, Musumeci, O, Angelini, C, Astrea, G, Bello, L, Bruno, C, Comi, GP, Di Fruscio, G, Piluso, G, Di Iorio, G, Ergoli, M, Esposito, G, Fanin, M, Farina, O, Fiorillo, C, Garofalo, A, Giugliano, T, Magri, F, Minetti, C, Moggio, M, Passamano, L, Pegoraro, E, Picillo, E, Sampaolo, S, Santorelli, FM, Semplicini, C, Udd, B, Toscano, A, Politano, L & Nigro, V 2018, 'Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease', Neuromuscular Disorders, vol. 28, no. 7, pp. 586-591. https://doi.org/10.1016/j.nmd.2018.03.011
Savarese, Marco ; Torella, Annalaura ; Musumeci, Olimpia ; Angelini, Corrado ; Astrea, Guja ; Bello, Luca ; Bruno, Claudio ; Comi, Giacomo Pietro ; Di Fruscio, Giuseppina ; Piluso, Giulio ; Di Iorio, Giuseppe ; Ergoli, Manuela ; Esposito, Gaia ; Fanin, Marina ; Farina, Olimpia ; Fiorillo, Chiara ; Garofalo, Arcomaria ; Giugliano, Teresa ; Magri, Francesca ; Minetti, Carlo ; Moggio, Maurizio ; Passamano, Luigia ; Pegoraro, Elena ; Picillo, Ester ; Sampaolo, Simone ; Santorelli, Filippo Maria ; Semplicini, Claudio ; Udd, Bjarne ; Toscano, Antonio ; Politano, Luisa ; Nigro, Vincenzo. / Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease. In: Neuromuscular Disorders. 2018 ; Vol. 28, No. 7. pp. 586-591.
@article{0a75a68c5424436d9c2d60dda38ec9ed,
title = "Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease",
abstract = "Mutations in the GAA gene may cause a late onset Pompe disease presenting with proximal weakness without the characteristic muscle pathology, and therefore a test for GAA activity is the first tier analysis in all undiagnosed patients with hyperCKemia and/or limb-girdle muscular weakness. By using MotorPlex, a targeted gene panel for next generation sequencing, we analyzed GAA and other muscle disease-genes in a large cohort of undiagnosed patients with suspected inherited skeletal muscle disorders (n = 504). In this cohort, 275 patients presented with limb-girdle phenotype and/or an isolated hyperCKemia. Mutational analysis identified GAA mutations in ten patients. Further seven affected relatives were identified by segregation studies. All the patients carried the common GAA mutation c.-32-13T >G and a second, previously reported mutation. In the subcohort of 275 patients with proximal muscle weakness and/or hyperCKemia, we identified late-onset Pompe disease in 10 patients. The clinical overlap between Pompe disease and LGMDs or other skeletal muscle disorders suggests that GAA and the genes causing a metabolic myopathy should be analyzed in all the gene panels used for testing neuromuscular patients. However, enzymatic tests are essential for the interpretation and validation of genetic results.",
keywords = "GAA, Gene panels, HyperCKemia, Late onset Pompe disease (LOPD), LGMD, Metabolic myopathies",
author = "Marco Savarese and Annalaura Torella and Olimpia Musumeci and Corrado Angelini and Guja Astrea and Luca Bello and Claudio Bruno and Comi, {Giacomo Pietro} and {Di Fruscio}, Giuseppina and Giulio Piluso and {Di Iorio}, Giuseppe and Manuela Ergoli and Gaia Esposito and Marina Fanin and Olimpia Farina and Chiara Fiorillo and Arcomaria Garofalo and Teresa Giugliano and Francesca Magri and Carlo Minetti and Maurizio Moggio and Luigia Passamano and Elena Pegoraro and Ester Picillo and Simone Sampaolo and Santorelli, {Filippo Maria} and Claudio Semplicini and Bjarne Udd and Antonio Toscano and Luisa Politano and Vincenzo Nigro",
year = "2018",
doi = "10.1016/j.nmd.2018.03.011",
language = "English",
volume = "28",
pages = "586--591",
journal = "Neuromuscular Disorders",
issn = "0960-8966",
publisher = "Elsevier Ltd",
number = "7",

}

TY - JOUR

T1 - Targeted gene panel screening is an effective tool to identify undiagnosed late onset Pompe disease

AU - Savarese, Marco

AU - Torella, Annalaura

AU - Musumeci, Olimpia

AU - Angelini, Corrado

AU - Astrea, Guja

AU - Bello, Luca

AU - Bruno, Claudio

AU - Comi, Giacomo Pietro

AU - Di Fruscio, Giuseppina

AU - Piluso, Giulio

AU - Di Iorio, Giuseppe

AU - Ergoli, Manuela

AU - Esposito, Gaia

AU - Fanin, Marina

AU - Farina, Olimpia

AU - Fiorillo, Chiara

AU - Garofalo, Arcomaria

AU - Giugliano, Teresa

AU - Magri, Francesca

AU - Minetti, Carlo

AU - Moggio, Maurizio

AU - Passamano, Luigia

AU - Pegoraro, Elena

AU - Picillo, Ester

AU - Sampaolo, Simone

AU - Santorelli, Filippo Maria

AU - Semplicini, Claudio

AU - Udd, Bjarne

AU - Toscano, Antonio

AU - Politano, Luisa

AU - Nigro, Vincenzo

PY - 2018

Y1 - 2018

N2 - Mutations in the GAA gene may cause a late onset Pompe disease presenting with proximal weakness without the characteristic muscle pathology, and therefore a test for GAA activity is the first tier analysis in all undiagnosed patients with hyperCKemia and/or limb-girdle muscular weakness. By using MotorPlex, a targeted gene panel for next generation sequencing, we analyzed GAA and other muscle disease-genes in a large cohort of undiagnosed patients with suspected inherited skeletal muscle disorders (n = 504). In this cohort, 275 patients presented with limb-girdle phenotype and/or an isolated hyperCKemia. Mutational analysis identified GAA mutations in ten patients. Further seven affected relatives were identified by segregation studies. All the patients carried the common GAA mutation c.-32-13T >G and a second, previously reported mutation. In the subcohort of 275 patients with proximal muscle weakness and/or hyperCKemia, we identified late-onset Pompe disease in 10 patients. The clinical overlap between Pompe disease and LGMDs or other skeletal muscle disorders suggests that GAA and the genes causing a metabolic myopathy should be analyzed in all the gene panels used for testing neuromuscular patients. However, enzymatic tests are essential for the interpretation and validation of genetic results.

AB - Mutations in the GAA gene may cause a late onset Pompe disease presenting with proximal weakness without the characteristic muscle pathology, and therefore a test for GAA activity is the first tier analysis in all undiagnosed patients with hyperCKemia and/or limb-girdle muscular weakness. By using MotorPlex, a targeted gene panel for next generation sequencing, we analyzed GAA and other muscle disease-genes in a large cohort of undiagnosed patients with suspected inherited skeletal muscle disorders (n = 504). In this cohort, 275 patients presented with limb-girdle phenotype and/or an isolated hyperCKemia. Mutational analysis identified GAA mutations in ten patients. Further seven affected relatives were identified by segregation studies. All the patients carried the common GAA mutation c.-32-13T >G and a second, previously reported mutation. In the subcohort of 275 patients with proximal muscle weakness and/or hyperCKemia, we identified late-onset Pompe disease in 10 patients. The clinical overlap between Pompe disease and LGMDs or other skeletal muscle disorders suggests that GAA and the genes causing a metabolic myopathy should be analyzed in all the gene panels used for testing neuromuscular patients. However, enzymatic tests are essential for the interpretation and validation of genetic results.

KW - GAA

KW - Gene panels

KW - HyperCKemia

KW - Late onset Pompe disease (LOPD)

KW - LGMD

KW - Metabolic myopathies

UR - http://www.scopus.com/inward/record.url?scp=85047872795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047872795&partnerID=8YFLogxK

U2 - 10.1016/j.nmd.2018.03.011

DO - 10.1016/j.nmd.2018.03.011

M3 - Article

AN - SCOPUS:85047872795

VL - 28

SP - 586

EP - 591

JO - Neuromuscular Disorders

JF - Neuromuscular Disorders

SN - 0960-8966

IS - 7

ER -